Article Text

Download PDFPDF

2022-RA-1480-ESGO TRANSLACOL project: digital-PCR human papilloma virus (HPV) detection for recurrence prediction in early cervical cancer patients without pelvic lymph node invasion
  1. Rosa Montero Macías1,
  2. Nicolas Robillard2,
  3. Thomas Bruneau2,
  4. Coronado Pluvio3,
  5. Mélanie Boulhic2,
  6. Marie-Aude Le Frére-Belda4,
  7. Ivana Stankovic4,
  8. Martina Aida Angeles5,
  9. Eliane Mery6,
  10. Pascal Rigolet7,
  11. Cecile Badoual4,
  12. Patrice Mathevet8,
  13. Anne-Sophie Bats9,
  14. Valérie Taly10,
  15. David Veyer2,
  16. Fabrice Lecuru11 and
  17. Helene Pere2
  1. 1Gynecologic and Obstetrics, Simone Veil Hospital, Eaubonne, France
  2. 2Virology Laboratory, European Georges Pompidou Hospital, Paris, France
  3. 3Women’s Health Institute José Botella Llusiá, Hospital Clínico San Carlos, Fundación de Investigación del Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, Spain
  4. 4Pathology Department, European Georges Pompidou Hospital, Paris, France
  5. 5Department of Surgical Oncology, Institut Universitaire du Cancer Toulouse Oncopole – Institut Claudius Regaud, Toulouse, France
  6. 6Pathology Department, Institut Universitaire du Cancer Toulouse Oncopole – Institut Claudius Regaud, Toulouse, France
  7. 7Université Paris-Saclay, Institut Curie, CNRS UMR 9187, Inserm U1196, Orsay, France
  8. 8Centre hospitalier universitaire vaudois (CHUV), Lausanne, Switzerland
  9. 9Gynecologic and Breast Oncologic Surgery Department, European Georges Pompidou Hospital, Paris, France
  10. 10INSERM, Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, Université de Paris and Sorbonne Université, Paris, France
  11. 11Breast, gynecology and reconstructive surgery unit. Curie Institute., Paris, France


Introduction/Background In early cervical cancer (ECC) patients with nodal metastasis (N+) present worse survival. However, 10–15% of patients without nodal metastasis (N0) present the same survival to N+ patients.As in cervical cancer, HPV DNA could be assimilated to tumoral DNA, we evaluate the presence of HPV DNA in pelvic Sentinel lymph nodes (SLN) by new ultrasensitive droplet-based digital polymerase chain reaction (ddPCR) as a biomarker of survival.

Methodology Inclusion criteria: EEC patients who underwent pelvic SLN detection N0 in pelvic lymph nodes. Associated pelvic lymph nodes samples were available for 60 patients with HPV16, HPV18 or HPV33 positive tumours. In SLN, after DNA extraction, HPV16 E6, HPV18 E7 and HPV33 E6 gene were respectively targeted and detected by ultrasensitive ddPCR optimized on two different platforms, the RainDrop Digital PCR System (RainDance Technologies, Bio-Rad, Hercules, CA) or the Biorad system.We compare two groups according to HPV DNA in SLN: positive or negative.

Results There was no difference between the negative HPV DNA SLN group and the positive HPV DNA SLN group in terms of patients and surgical-pathological characteristics, treatments and time of follow-up. Two patients in negative HPV DNA SLN group and 6 in positive HPV DNA SLN group presented recurrence and the mean time of recurrence was respectively 43.5 and 29.2 month, but, these differences are not statistical significant.However, all of the 4 deaths listed in our study occurred in the positive HPV DNA SLN group for which the 10 years Overall survival (OS) is thus significantly decreased.

Abstract 2022-RA-1480-ESGO Figure 1

Conclusion Our results show worst OS in patients with detected HPV DNA compared to patients without detected HPV DNA in their SLN and the same tendency is observed for PFS without significance. Thus, HPV DNA in SLN detected by ultrasensitive ddPCR could represent an interesting prognosis biomarker in N0 ECC.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.